Bio-Imaging elects Olukotun to board

Bio-Imaging Technologies has chosen Adeoye Olukotun, MD, to serve as a director on the board, effective Monday.

Olukotun is co-founder and, since 2004, chief medical officer (CMO) of VIA Pharmaceuticals, a publicly traded biotechnology company based in San Francisco focused on the treatment of cardiovascular disease.

He is a board-certified cardiologist with more than twenty-five years of experience in clinical research and drug development in the pharmaceutical industry, according to the Newton, Pa.-based company. Before joining VIA, Olukotun founded CR Strategies, a clinical research and development consulting firm in Princeton, N.J., and served as its CEO from 2000 to 2003. He also was CMO of Esperion Therapeutics, a cardiovascular drug development company, until its acquisition by Pfizer in 2004.

Around the web

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.